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A B S T R A C T   
The autologous lipoaspirate processing allows to obtain a tissue product to be transplanted for regenerative 
purposes in multiple pathological sites, such as the knee joint affected by osteoarthritic disease. Recently, 
multiple protocols and devices have been designed for lipoaspirate processing. These protocols and devices do 
not use enzymatic digestion and respect the principles of the so-called "minimal manipulation in a closed system". 
In this study, we performed a systematic review of the literature to identify studies in which osteoarthritis was 
treated by minimally manipulated intra-articular SVF injection and assessment of therapeutic response was re-
ported. All bias scores were analyzed based on the Coleman methodology score modified by Kon et al. [27] and a 
subsequent linear classification system of articles was proposed. We identified 12 clinical trials in which clinical 
evaluations were performed inconsistently using different scales of analysis. All studies reported a significant 
decrease in the patient’s symptomatic discomfort, with improvement in joint function and reduction in pain. 
Most studies do not reach a high-quality level on the linear scale based on the Coleman-Kon scores. Although the 
treatment of osteoarthritis of the knee with regenerative methods is undoubtedly of interest, being aimed at 
healing the disease, this study highlights that the trials are numerically limited, and qualitatively not optimal 
according to the Coleman-Kon score. Reasonably, greater standardization of devices protocols will be desirable in 
the future. The high clinical potential offered by these methods could be optimized for all patients.   
1. Introduction 
Rheumatic diseases comprise a heterogeneous group of chronic dis-
orders affecting the locomotor system and are the main causes of 
disability in the adult population [1]. In particular, osteoarthritis (OA) is 
among the most common [2] and involves a progressive degeneration 
and aberrant remodelling of the joint components, culminating in a 
symptomatic picture of pain, loss of functionality and disability. More-
over, a high prevalence of physical and psychological comorbidities is 
commonly reported [3,4]. Although the causes of OA are not yet well 
defined, it is known that the uncontrolled inflammatory response and 
deregulations of the released cytokine network have been shown to be 
deeply involved in the etiology and symptomatic manifestation of this 
pathology [5,6]. 
In the last few years, a new therapeutic approach based on the use of 
autologous adipose tissue transplants for the treatment of rheumatic 
diseases (e.g., OA) has spread [7]. This therapeutic perspective has 
implied a strong impetus for studies aimed at defining the cellular 
components that constitute adipose tissue [8]. Initially considered only 
inert filler, today its role has been extended to dynamic tissue with 
regenerative properties in multiple contexts of tissue injury and in-
flammatory conditions, including rheumatic pathology and therefore 
OA [9]. The biological basis of this regenerative potential is due to the 
relatively high content of mesenchymal stromal stem cells (Adipose 
Derived Stem Cell, ADSC), located in the Stromal Vascular Fraction 
(SVF) [8,10]. These are progenitor cells endowed with multilinear 
plasticity towards adipocytic, chondrocytic, and osteocytic differentia-
tion and with regenerative, immunomodulatory, and pro- angiogenic 
properties [7,11]. In the context of OA, the use of autologous ADSC 
transplantation is an extraordinary potential tool to allow not only the 
shutdown of chronic inflammatory processes, but also for a potential 
regenerative purpose of the synovium and the chondral surface [9]. 
In recent years, the literature on musculoskeletal diseases has been 
enriched with numerous studies aimed at evaluating the clinical 
response to ADSCs-based treatments [7,12]. The standard laboratory 
procedure for isolating ADSCs involves an enzymatic digestion of tissue 
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with collagenase [13]. The major disadvantages of this procedure are 
the requirement of considerable processing time, and the impossibility 
to considering it as a so-called “minimal tissue manipulation procedure”, 
a fundamental prerogative for the use of stem cells in clinical practice 
[14]. In fact, the Good Manufacturing Practice regulations [15] of the 
European Parliament and Council (EC regulation no. 1394/2007), EMA 
(European Medical Agency) and FDA (Food and Drug Administration) 
(FDA-2017-D-6146) ban the enzymatic manipulation of stem cells in the 
clinical setting. 
The need to reduce processing times (for an immediate clinical use) 
and regulatory restrictions on the degree of human lipoaspirate 
manipulation have led to the development of numerous devices for the 
non-enzymatic mechanical processing of harvested adipose tissue 
[16–18]. These protocols, with inherent variations, are characterized by 
three common phases: harvesting, processing, and reinjection [18]. The 
harvesting is performed in easily accessible anatomical regions such as 
the subcutaneous tissue, in order to provide a product to be re-injected 
in the areas affected by pathological alterations. In particular, by 
comparing the adipose samples extracted from thigh and abdomen, the 
former provides a higher number of ADSCs [19]. Processing includes 
one or more manipulation techniques that commonly vary depending on 
the choice of surgeon and site of re-injection [18]. 
Several reviews of clinical studies aimed at evaluating SVF therapy in 
knee OA are already present in the literature, but all also include 
enzymatic-based trials conducted in non-US or non-EU areas [20–25], 
and some define the comparison between ADSC and the bone 
marrow-derived mesenchymal stromal stem cells therapy [20–24]. None 
of these reviews focused on the types of devices used for the mechanical 
Fig. 1. PRISMA flowchart of the literature review.  
U. Lavagnolo et al.                                                                                                                                                                                                                             
Biomedicine & Pharmacotherapy 142 (2021) 111997
3
lipoaspirate processing. Considering this lacuna, we believe that an 
updated and thoughtful review is necessary, to evaluate the state of the 
art of knee OA therapy based on the use of technological devices and 
clinically applicable protocols, already present in today’s clinical 
practice. 
2. Material and methods 
We performed a systematic literature review of the articles published 
up to June 2021, consulting the PubMed, Embase, Medline Ovid and the 
Cochrane Central Register of Controlled Trials databases; search strings 
included the terms: "stromal vascular fraction - SVF" OR / AND "adipose 
(derived) stem / stromal cell - ASC/ADSC" AND "knee" AND "osteoar-
thritis", differently combined. 
A PRISMA flowchart [26] of the selection method is reported in  
Fig. 1. Duplicated works were removed. Then, the inclusion criteria for 
the remaining articles were applied: only peer-reviewed studies, written 
in English; any study design; based on the intra-articular injection of 
minimally manipulated SVF and on the evaluation of the therapeutic 
response aimed at the regenerating the articular cartilage. Conference 
presentations, narrative reviews, editorials, and expert opinion were 
excluded, in order to integrate studies with clinical evidence. 
The exclusion criteria subsequently applied were: studies that 
included an enzymatic manipulation of the collected tissue or that in-
tegrated an enzymatic approach with the mechanical one. Furthermore, 
if no statistical analyzes were reported in the studies, the articles were 
excluded from the analysis. 
The selected articles were first analyzed on the basis of their 
conceptualization (study design, experimental model, clinical evalua-
tion tools used). Clinical outcomes were highlighted and some consid-
erations were made on the technical instruments and procedures 
applied. All bias assessments were evaluated according to the Coleman 
methodology score modified by Kon et al. [27] (Table 1). This score is a 
recognized standard used to assess the quality level of cartilage regen-
eration studies, not the outcome of the procedure itself. It consists of a 
general assessment part (A) and a specific assessment part (B) for joint 
cartilage studies. In part A, scores are assigned to 8 parameters (study 
size, follow-up duration, number of surgeries, type of study, description 
of surgery, description of postoperative rehabilitation, imaging in-
vestigations, histological investigations), with a maximum of 75 points. 
Part B considers 3 parameters (outcome criteria, clinical outcome 
assessment procedure, description of the subject selection process), with 
a maximum of 25 points. The total is obtained from the sum of items, 
which composed both parts (maximum 100 points). Given the absence 
of a defined classification of the numerical data provided by the score, 
we utilized a subjective evaluation based on the linearity of the scale: 
<25 points are considered scarce; 25–50 points not optimal; 50–75 
points partially optimal; >75 points optimal. 
3. Results 
After the duplicates were removed, 264 studies were reviewed. 36 
human trials (14%) were selected utilizing the inclusion criteria. 12 
studies (5%) remained after application of the exclusion criteria 
(28–39). Table 2 summarizes the experimental model, study design, 
processing device, follow-up period, and the most relevant results 
obtained. 
Clinical evaluations were performed in a non-homogeneous way and 
different analysis scales were used: Knee Injury and Osteoarthritis 
Outcome Score (KOOS) [31,33–35,39]; Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) [28,30,37]; Visual Analog 
Scale (VAS) [29–35,37,38]; Tegner Lysholm Knee (TLK) [34,35]; In-
ternational Knee Documentation Committee (IKDC) [34,35]; Emory 
Quality of Life (EQOL) [33]; Japanese Knee Osteoarthritis Measure 
(JKOM) [30]; International Knee Society (IKS) knee and function scores 
[38]. Nuclear magnetic resonance (MRI) imaging were also performed 
in four studies [28,29,32,37]. Only in Roato et al. [37] evaluations of 
immunohistochemistry (IHC) and scanning electron microscopy (SEM) 
were included. 
For Peretti et al. [36] it was not possible to obtain the full text; with 
this assumption, the quantitative assessment using the Coleman-Kon 
score was not conducted (Fig. 1), while clinical data were obtained 
from the abstract. 
3.1. Clinical findings 
Our survey reports that 7 studies are prospective non-randomized 
trials [29–32,34,35,37], while 2 are prospective randomized [28,36] 
and 3 retrospective [33,38,39] trials. 
Mautner et al. [33] included the largest number of knees in their 
study (106 knees, 76 patients). Onoi et al. [31] presented a case report of 
two patients, which cannot properly be consider as a clinical trial (3 
knees). 9 studies (75%) were conducted with at least 12 months of 
follow-up [28,29,32–35,37–39], and 3 studies (25%) covered 6 months 
of follow-up [30,31,36]. 
In all studies, the clinical outcomes highlight a significant decrease in 
the patient’s symptomatic distress, with improvement in joint function 
and reduction of pain. 
Specifically, 8 out of 12 studies used the VAS pain scale to evaluate 
clinical outcomes. Boric et al. [29], and Hudetz et al. [32] reported an 
improvement in activity VAS from 7.73 ± 1.55–3.4 ± 1.65, and from 
7.33 ± 1.72–3.17 ± 1.98, respectively. Resting VAS decreased from 
4.45 ± 2.42–0.55 ± 1.04 for Boric et al. [29], and from 
3.94 ± 2.56–0.56 ± 1.2 for Hudetz et al. [32]. Roato et al. [37] reported 
an improvement in overall VAS from 7.05 ± 0.4–3.34 ± 0.6. Mautner 
et al. [33], Russo et al. [34], Schiavone Panni et al. [38], and Yokota 
et al. [30] showed an improvement in VAS of 37%, 55%, 40% and 40%, 
respectively Onoi et al. [31] reported an improvement of at least 75%. 
Table 1 
Coleman methodology score modified by Kon-Verdonk [27].  
Part A  Score 
1 Study size: number of lesions  
>60 | 41–60 | 20–40 | <20, not stated 10 | 7 | 4 | 0 
2 Mean follow-up, months  
>60 | 24–60 | 12–24 | <12, not stated 10 | 5 | 2 | 0 
3 Number of surgical procedures included in each outcome  
One procedure 10 
More than 1 surgical: <10% patients | >10% patients 7 | 4 
Not stated, unclear 0 
4 Type of study  
Randomized control trial 15 
Prospective cohort study 10 
Retrospective cohort study 0 
5 Description of surgical procedure given  
Adequate | Fair | Inadequate 5 | 3 | 0 
6 Description of postoperative rehabilitation  
Well described | Not adequately described | Protocol not 
reported 
5 | 2 | 0 
7 Inclusion MRI outcome/assessment  
Reported for >80% of patients | <80% of patients 10 | 5 
Not reported 0 
8 Inclusion histological outcome/assessment  
Reported for >50% of patients | <50% of patients 10 | 5 
Not reported 0 
Part B  Score 
1 Outcome criteria  
Clearly defined 2 
Outcome criteria (good reliability and sensitivity) 3 
2 Procedure for assessing clinical outcomes  
Patients recruited 3 
Investigator independent of surgeon 4 
Completion of assessment by patients themselves 2 
3 Description of subject selection process  
Selection criteria reported and unbiased 3 
Recruitment rate reported: >80% | <80% 5 | 3  
TOT 100 points  
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Four out of 12 studies utilized WOMAC index. Cattaneo et al. [39], 
Garza et al. [28], and Yokota et al. [30] found an improvement in this 
index of at least 79%, 68.2%, and 32%. Roato et al. [37] reported the 
change in score from 45.9 ± 2.8–13.0 ± 2.3. 
Another 4 studies reported an improvement in the KOOS index of at 
least 73% [39], and 18% [31], about 30% [33], and 64% [34]. 
When performed, MRI did not consistently provide cartilage 
morphological improvement data. Peretti et al. [36] emphasized that 
imaging investigations were still ongoing and therefore not available. 
Garza et al. [28] found no changes, while Boric et al. [29], and Hudetz 
et al. [32] reported an increase in the content of cartilaginous glycos-
aminoglycans in the treated joints with a variation of the order of 15%. 
Only two studies partially characterized the processed fat, from the 
biological point of view. With histological and immunohistochemical 
investigations on biopsy samples taken in the context of post-treatment 
prosthetics, Roato et al. [37] reported the presence of a layer of cartilage 
neoformation in the joint region characterized by osteochondral lesion. 
In the context of a second-look arthroscopy (6 months after treatment), 
Onoi et al. [31] reported the presence of an almost total coverage of 
cartilage defects, with repair of the compromised meniscal areas (di-
mensions of the filled areas: 2.5–3 ×1.5 cm in the first patient, 
1.5–2 ×1.5 cm in the second patient). 
As already highlighted, Onoi et al. [31] presented a case report of 
two patients: despite this and considering the limitation of the studies 
found, the report was still integrated into our investigation. The clinical 
evaluations of this study, although reported, are not considered statis-
tically significant for the non-representative cohort. 
3.2. Technical findings 
In 7 studies (58%) (Fig. 2) the device adopted was Lipogems® [29, 
32–35,38,39]. By performing a manual shaking, this mechanical device 
allows the fragmentation of the lipoaspirate by means of steel balls. The 
product obtained is filtered and injected directly in the joint, without 
Table 2 
Clinical studies regarding the minimal manipulated SVF use in the treatment of knee OA.   
Therapeutic protocol Evaluation Study design Device FU Conclusion 
Garza et al.  
[28] 
39 patients, 2 groups: high 
/low MFAT dose. 
WOMAC score; MRI Prosp, rand 
contr trial 
GID SVF-2® (GID 
Group) 
12 months Dose-dependent decrease of symptoms 
and pain. MRI outcome: no changes. 
Boric et al.  
[29] 













Significant increase of GAG content; 
significant clinical improvement. 
Mautner et al. 
[33] 
76 patients (BMAC 41, 
MFAT 35 inject) and 106 
knees (BMAC 58, MFAT 48 
inject). 
KOOS; EQOL; VAS. Retrosp Lipogems® 
(Lipogems 
International SpA) 
1 year For both groups: improvement in EQOL, 
VAS, and all KOOS parameters. Post 
procedure scores: not significant 
different. 
Onoi et al.  
[31] 








6 months VAS and KOOS improved. At 6th months 
FU: coverage of almost all cartilage 
defect areas. 
Russo et al.  
[34] 
30 patients: MFAT inject - 24 
with associated surgery, 6 
arthroscopy only. 










Clinical outcomes improvement: 41% 
TLK; 55% VAS; 55% IKDC; 64% KOOS. 
Peretti et al.  
[36] 
2 groups: AD + intra- 








6 months Outcomes: no significant differences. 
Roato et al.  
[37] 
20 patients: MFAT inject. VAS; WOMAC; 
biopsies; IHC; SEM. 
Prosp, non- 
rand trial 
Centrifugation 18 months Pain reduction and increased 
functionality. Biopsy: layer of newly 
formed tissue. 
Schiavone 
Panni et al.  
[38] 
52 patients: AD + MFAT 
inject. 





24 months Clinical and functional scores increasing 
at a mid-term follow-up. 
Cattaneo et al. 
[39] 







12 months Clinical improvement in 92% patients, 
100% satisfied. 
Hudetz et al.  
[32] 
17 patients, 32 knees: MFAT 
inject. 





12 months Increase in knee GAG content and in 
VAS score. 
Yokota et al.  
[30] 









6 months At 1 month FU: overall improvement. At 
6th months FU: 35% JKOM; 32% 
WOMAC; 40% VAS improvement. 
Russo et al.  
[35] 
30 patients: MFAT inject - 24 
with associated surgery, 6 
arthroscopy only. 







12 months Total median improvement of 20 points 
in IKDC-subjective and total KOOS, and 
of 24 and 31 points in VAS and TLK 
respectively. 
AD: arthroscopic debridement, BMAC: bone marrow aspirate concentrate, contr: controlled, dGEMRIC: delayed gadolinium (Gd)-enhanced magnetic resonance im-
aging of cartilage, EQOL: Emory Quality of Life, FU: Follow-up, IHC: Immunohistochemistry, IKDC: International Knee Documentation Committee, inject: injection, 
JKOM: Japanese Knee Osteoarthritis Measure, KOOS: Knee Injury and Osteoarthritis Outcome Score, MFAT: micro-fragmented adipose tissue, MRI: Magnetic Reso-
nance Imaging, prosp: prospective, rand: randomized, retrosp: retrospective, SEM: scanning electron microscopy, TLK: Tegner Lysholm Knee, VAS: Visual Analog 
Scale, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. 
Fig. 2. Percentage of devices used in the different studies investigated.  
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performing centrifugation [16]. 
Garza et al. [28] used GID SVF-2®, which is a recent modular tissue 
processing platform based on a manual pureeing of the lipoaspirate 
[40]; in the literature, we found only two other trials using the same 
device [41,42]. Centrifugation is performed at 600 g for 6 min; then, 
after a further pureeing, for another 4 min. 
Yokota et al. [30], and Onoi et al. [31] reported the use of the Cel-
lution® centrifuge [43]. This is a CE-marked technology developed by 
Cytori to allow real-time access to a concentrated single cell suspension 
of autologous SVF. The system integrates mechanical manipulation with 
enzymatic processing, replacing collagenase with two process reagents 
and centrifugation performed at 400 g for 10 min. Having CE certifica-
tion, this procedure is interpreted as applicable in our clinical context. It 
should be noted that ADSCs are the result of culturing the 
plastic-adherent fraction of the SVF from fat, since the precursors of the 
ADSCs already reside in the SVF and cannot be separated from it. 
Roato et al. [37] used a simple centrifugation at 3000 rpm for 3 min 
to separate the oily supernatant from the SVF. 
In the trial of Peretti et al. [36] the exact protocol for SVF processing 
could not be recognized; it had to be a simple centrifugation without the 
use of particular devices. 
3.3. Coleman-Kon methodology score 
Although clinical results were positive, the Coleman-Kon method-
ology score (Table 3, Fig. 3) was extremely poor, with a mean of 
46.4 ± 12.5 points, 67 maximum points for Roato et al. [37], and 33 
minimum point for Cattaneo et al. [39]. For three of the studies 
considered [30,32,37], the score was already available in the literature 
[24]. After comparing the congruity of the data obtained by Di Matteo 
et al. [24] with our ratings, we decided to report their scores in this 
study. 
Considering all the obtained Coleman-Kon scores, we deduced that 
the risk of bias is high as most of the selected studies are not at a high- 
quality level. With reference to our subjective classification, no study 
has a qualitatively optimal score (>70 points). 
4. Discussion 
Among the sources of mesenchymal stromal stem cells, adipose tis-
sue is one of the main [7], easier to access with minimal discomfort for 
the patient. The use of adipose tissue for regenerative purposes has been 
practiced for a long time, but recently there has been an increase in 
studies aimed at investigating the biological potential [7,10,44]. The 
possibility of having a regenerative chondrocytes source could therefore 
guarantee a restoration of compromised joint function [45]. In this 
perspective, the use of autologous ADSC transplantation seems to be an 
extraordinary potential tool to allow not only the shutdown of chronic 
inflammatory processes, but also for a potential regenerative purpose of 
the synovium and the chondral surface. The clinical application of the 
processed lipoaspirate underlies the use of devices suitable for minimal 
manipulation, i.e. capable of leaving the isolated stem niche unaltered to 
be transplanted into the pathological joint. It should be noted that the 
fact that cultured ADSCs have chondrogenic capacity and suppression of 
inflammation does not guarantee that their precursors in fat / SVF will 
do the same. Vice versa, the fact that fat / SVF administration tempers 
inflammation and reduces pain does not mean that this is governed by 
ADSCs. Further studies are needed to verify both the anti-inflammatory 
potential and the regenerative potential of the graft. 
The present systematic review clearly demonstrates that the avail-
able literature is particularly scarce regarding the use of devices for 
minimally invasive therapy based on processed lipoaspirate. This could 
be due to ongoing investigations not yet published, with reference to the 
topicality and innovation of this field of study. 
In the studies considered, the most evaluated protocol is Lipogems®, 
which was used in perspective, retrospective, randomized and non- 
randomized trials [29,32–35,38,39]. This evidence is particularly rele-
vant: Lipogems® is one of the best documented devices in the literature, 
perhaps for the protocol known for more than ten years. 
From a clinical point of view, the treatments significantly increased 
clinical outcomes in all these studies. 
Considering the Coleman-Kon score, the evidence suggests low 
methodological quality in the studies evaluated. In general, the short 
average follow-up and the type of retrospective study are factors that 
lower the score. Furthermore, in many papers, because the inclusion and 
exclusion criteria were not well reported, the recruitment rate was not 
evaluated, introducing another source of bias. Moreover, although all 
Table 3 



















Roato et al. [37] 67 0 2 10 10 5 5 10 10 5 7 3 
Garza et al. [28] 61 4 2 10 15 5 0 10 0 5 7 3 
Boric et al. [29] 57 0 5 10 10 5 2 10 0 5 7 3 
Hudetz et al. [32] 53 4 2 10 10 5 0 10 0 5 7 0 
Russo et al. [34] 51 4 5 4 10 5 5 0 0 5 5 8 
Russo et al. [35] 49 4 2 4 10 5 5 0 0 5 5 8 
Mautner et al. [33] 34 10 2 10 0 5 0 0 0 2 5 0 
Onoi et al. [31] 37 0 0 10 10 5 2 0 0 5 2 3 
Schiavone Panni 
et al. [38] 
34 7 5 4 0 5 0 0 0 5 5 3 
Yokota et al. [30] 34 0 0 10 10 5 2 0 0 2 5 0 
Cattaneo et al. [39] 33 4 2 4 0 5 5 0 0 5 5 3 
Peretti et al. [36] – – – – – – – – – – – – 
Legend: TOT = total; Foll-up = mean follow-up; Surg proc = surgical procedures descriptions; Postop rehab = post-operative rehabilitation; MRI = magnetic reso-
nance imaging; Histo = histological outcome; Assessm of CO = assessment of clinical outcome; - = data not available. 
Fig. 3. Violin plot of Coleman-Kon’s scores. A poor quality of the investigated 
studies and a high risk of bias induction are highlighted. 
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authors adequately described the procedure (with the exception of 
Peretti et al. [36]), in many studies [34–36,38,39] patients underwent 
concomitant surgeries such as arthroscopic debridement, micro-
fractures, or high tibial osteotomy, thus preventing a clear under-
standing of the real contribution and clinical potential of stem cell-based 
treatment. The basic questions about the number of cells administered, 
the optimal number of injections to achieve the best therapeutic effect, 
and the superiority of one method of preparation over another still re-
mains unanswered. Post-operative rehabilitation was described in seven 
studies [29–31,34,35,37,39] (but correctly defined exclusively in four 
papers [34,35,37,39]), while the outcomes of MRI were reported in only 
four studies [28,29,32,37] and the histological outcome only by Roato 
et al. [37]. 
The numeric expansion of available kits (i.e., devices) for the treat-
ment of patients with knee OA through mechanical lipoaspirate pro-
cessing is evident [24]. This could be a great opportunity to provide a 
concrete therapeutical chance even for a pathology still strictly limited 
to invasive demolition surgery. Nevertheless, an expanding market for 
these technologies does not always mean improving the standard of 
care, especially when there is a lack of comparative trials evaluating the 
effectiveness of a new treatment versus established ones. Comparing the 
proportional use of these devices in today clinical practice with the 
documented trials available, a substantial deficit emerges: many devices 
have insufficient published scientific data to certify their clinical use. 
Finally, the question of inter-human variability has not yet been 
faced. This is a fundamental prerogative for the success of these bio-
logical therapies, because a particular “patient profile” could respond 
better to a specific biologic stimulus than another. This highlights the 
need for further research, dedicated to understanding the unique char-
acteristics of a specific stem cell-based product and the responses of a 
categorized joint environment. 
Expanding the number of treatment options available to patients 
with knee OA does not always improve the standard of care, especially 
when comparative trials assessing the quality of one new treatment 
versus others are lacking. Furthermore, the scarce use of scores such as 
the Coleman-Kon score prevents methodological comparison of different 
studies. The extraordinary clinical results obtained with the minimal 
non-enzymatic manipulated lipoaspirate processing should encourage 
research and stimulate new wide-ranging investigations to ensure strong 
validation and standardization of new therapeutic protocols. 
5. Conclusion 
This work took into consideration the potential offered by the use of 
technological tools for the processing of adipose tissue through minimal 
handling in a closed system. These devices are now widely used in 
clinical practice, but studies are still scarce, and few trials have been 
published to evaluate their efficacy in vivo. The very encouraging 
empirical results have provided a boost to production, saturating the 
market with multiple devices often lacking the published preclinical 
experimental standardization and with poorly defined usage protocols. 
In this review, we considered 12 clinical trials, in which devices for 
minimal manipulation of lipoaspirate were used for regenerative pur-
poses in the context of knee OA. It has been highlighted that, on the basis 
of the Coleman-Kon score, these trials are scarce quantitative and 
burdened by numerous methodological limitations (these evaluated by 
the Coleman-Kon score), which prevent an evaluation standardization 
and imply results that are difficult to compare. This review shows sig-
nificant clinical improvement of the osteoarthritic knee after treatment 
in all studies (assessed with clinical scores, sometimes by MR imaging 
and histological evaluation), regardless of the device used. Among the 
devices considered, Lipogems® is the most studied in available clinical 
trials. 
Reasonably, greater standardization of devices protocols will be 
desirable in the future, but only obtainable with qualitatively optimal 
and dedicated clinical studies for each device. In this way, the high 
clinical potential offered by these methods could be correctly optimized 
for defined patient populations. 
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